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A 35-year-old woman with persistent vaginal bleeding and a history of prior cesarean delivery was
diagnosed with cesarean scar pregnancy (CSP) by transvaginal ultrasonography at 7 weeks of gestation.
The patient was initially treated with a single dose of systemic methotrexate (MTX) injection. However,
both follow-up b-hCG levels and transvaginal ultrasonography had shown evidence of ongoing preg-
nancy. Finally, she was treated with hysteroscopic resectoscope, by which the gestational tissue was
removed completely. No intra-operative or post-operative complication occurred. Serum b-hCG level
returned to normal limit four weeks after the surgery. In our experience, systemic MTX injection pro-
vides an alternative choice of treatment for carefully selected women with CSP, and hysteroscopic
removal of CSP, which offers good prognosis, can serve both as the initial treatment and as the rescue
management after a failed MTX treatment attempt.
Copyright  2013, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
The incidence of cesarean scar pregnancy (CSP) is about 1 in 2000
pregnancies, which represents 6.15% of all ectopic pregnancies in
womenwith a prior cesarean delivery.1 Recently, more attention has
been given to this rare form of ectopic pregnancy due to the increase
in overall cesarean delivery rate and the improvement of earlier
diagnosis by high-resolution transvaginal ultrasonography. Current
management modalities include medical treatment with metho-
trexate (MTX) and the surgical procedures laparatomy, laparoscopy,
or hysteroscopy.2 Nevertheless, there is no standard protocol
regarding the treatment of CSP at present. In this report, we describe
a patient with CSP diagnosed by transvaginal ultrasound who was
initially treated with systemic MTX but eventually received hyster-
oscopic surgery after the failure of medical treatment.Case report
A 35-year-old woman, gravida 2, para 1, underwent cesarean
delivery 3 years previously, and her other past history wasdoscopy, Department of Ob-
tal at Linkou and Chang Gung
i-Shan, Taoyuan 333, Taiwan.
ee).
ia-PaciﬁcAssociationforGynecologicEunremarkable. This time, she was pregnant at 7 weeks of gestation
and visited our hospital for persistent vaginal spotting. Trans-
vaginal sonogram showed no intrauterine pregnancy but a gesta-
tional sac measuring 2.5  1.5 cm at the previous cesarean scar
defect suggested the diagnosis of CSP (Fig. 1A). Her serum human
chorionic gonadotropin (b-hCG) level was 34,313 mIU/mL. Medical
treatment with a single dose of MTX, 85 mg, was injected intra-
muscularly. Despite the medical treatment, follow-up serum b-hCG
levels had shown an increase on the 3rd and 6th day after MTX in-
jection (60,713 mIU/mL and 75,528 mIU/mL, respectively). Trans-
vaginal sonography was performed again on the 9th day and the
gestational sac was enlarged to 3.5  3.0 cm (Fig. 1B). Therefore,
hysteroscopic surgery was arranged on the 10th day. A continuous-
ﬂow 26F hysteroscopic resectoscope (Karl Stortz GmbH & Co.,
Tuttlingen, Germany) with a 90-degree wire loop electrode was
introduced under the guidance of transabdominal ultrasound. The
operative ﬁnding revealed a large cesarean scar defect embedded
with gestational tissues and blood clots. The resection was per-
formed using 80 W of cutting current followed by 100 W of coag-
ulating current created by an Aspen Excalibur (Aspen Labs,
Englewood, CO, USA) electrosurgical generator. The gestational
tissue was cut piece by piece and it was removed completely, along
with other necrotic debris and blood clots (Fig. 2). The base of the
defect was inspected thoroughly to ensure that there were no
remnants of chorionic villous tissue. Then, electrocauterization for
hemostasis was performed by a metallic roller-ball attached to thendoscopyandMinimally InvasiveTherapy.PublishedbyElsevierTaiwanLLC.All rightsreserved.
Fig. 1. (A) Transvaginal sonography showing a 2.5  1.5 cm gestational sac (arrow) over the previous cesarean scar defect before methotrexate (MTX) injection, which increased to
(B) 3.5  3.0 cm after 9 days despite MTX injection (arrow).
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and the estimated blood loss was less than 20mL. No perforation or
other complications occurred during the operation. The post-
operative course was uneventful and she was discharged on the 2nd
day after the surgery. Her serum b-hCG level returned to within
normal limits 4 weeks later.
Discussion
CSP is an infrequent type of ectopic pregnancywith an incidence
of 1:1800e1:2216 pregnancies. Treatment options include medical
treatment with local or systemic MTX injection and surgical
treatment via hysteroscopy or laparoscopy.2 Currently, there is not
enough evidence to favor one speciﬁc treatment over another.
Treatment should be individualized and several conditions must be
considered: hemodynamic stability, size of gestational sac, serum
b-hCG level, and preservation of fertility. Patients suitable for MTX
treatment should be hemodynamically stable, with low b-hCG level
(<5000 mIU/mL), compliant to receive regular follow-ups, and
without renal or hepatic dysfunction.1
In one study, the failure rate of a single systemic MTX injection
was demonstrated to be as high as 12 out of 21 cases requiring
additional doses of MTX or surgical intervention.3 Another study
showed that hysteroscopy following a failed MTX treatment
attempt offers advantages over local injection of MTX to theFig. 2. Transcervical hysteroscopic resection of gestational tissue piece by piece.gestational sac.4 However, a hysteroscopic approach requires an
experienced operator who is skillful at manipulating hysteroscopic
instruments and familiar with the orientation of the uterine cavity.5
Furthermore, it is indicated only for the CSP that grows inwardly
towards the uterine cavity. In the case of a pregnancy that grows
between the abdominal cavity and the bladder, a laparoscopic
approach may be the choice.6
In this report, systemic MTX treatment was given initially
because the patient was hemodynamically stable with no
contraindication to MTX injection. Nevertheless, hysteroscopic
removal of CSP was performed due to the failure of MTX treat-
ment. The insertion of the resectoscope and the resection of
gestational tissue were performed under the guidance of trans-
abdominal ultrasound. A recent study showed that real-time ul-
trasound guidance during a hysteroscopic surgery resulted in a
trend towards reducing the uterine perforation rate.7 Lapa-
roscopically assisted operative hysteroscopy was also shown to
possess the advantages of mobilization of the bladder, skeleto-
nization of the uterine vessels, immediate detection of uterine
and/or bladder perforation, and rapid management of hemor-
rhage.8 To prevent massive bleeding, bilateral uterine artery
ligation by laparoscopy or uterine artery embolization (UAE) may
be performed at the beginning of the procedure.9 In the case of
persistent bleeding after the removal of gestational tissue, intra-
uterine gauze compression or Foley tamponade may be tried
initially.4 Hysterectomy is reserved as the last resort when other
managements have failed to cease the bleeding. In the case of a
deeper implantation into the scar defect, laparoscopic surgery is
preferred for both resection of the gestational tissue and repair of
the defect to prevent the risk of uterine rupture in subsequent
pregnancies.5
In conclusion, systemic MTX injection is an alternative treat-
ment for carefully selected women with CSP, and hysteroscopic
removal of CSP provides good prognosis both as an initial treatment
and as management after failed MTX treatment.References
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